ET-743 3 HOUR INFUSION EVERY 3 WEEKS, COMPASSIVE USE

Not Applicable

• Conditions: -C923 Myeloid sarcoma; Myeloid sarcoma; C923

• Registration Number: PER-026-01
• Lead Sponsor: INSTITUTO DE ENFERMEDADES NEOPLASICAS,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2001-06-05
• Last Update Posted: 4 September 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Neutrophil count .1.5x10 9 / L
Platelet count .I00x10 9 / L
Creatinine clearance> 30 mL / min
Serum bilirubin: ULN (normal upper limit and total alkaline phosphatase ... LSN If the total alkaline phosphatase> ULN, liver alkaline phosphatase fraction and 5 ´- Nucleotidase should be ^ NSL AST, ALT <2.5 x ULN values
institutional laboratory
Albumin> 25 g / L.

Exclusion Criteria

NA

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br>Outcome name:Tumor measurement, physical examination<br>Measure:Efficacy<br>Timepoints:Before therapy and at the end of the study<br>

Secondary Outcome Measures

Name	Time	Method
<br>Outcome name:Resgistry of adverse events<br>Measure:Safety and Tolerability<br>Timepoints:When the event appears<br>